Ezra: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Ezra's website, https://joinezra.com, FDA Establishment Identifier (FEI) 3045074898, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify "Ezra" on the pictured label, suggesting Ezra is the compounder of those drugs when in fact it is not.”

2. 2

   “Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

www.joinezra.com and ezra.com both returned live storefronts when we checked in August 2026 (the bare joinezra.com domain without "www" 404s — that is a domain-configuration quirk, not evidence the business has closed).

Ezra expanded from full-body MRI scans into compounded GLP-1s, and this letter is about how that new product line was labeled, not about the scans it's known for or a finding that the medication is unsafe. A pictured label carrying the retailer's own brand name, when a separate pharmacy actually compounds the drug, is the specific thing FDA objected to — it's worth checking whose name is actually on the label before assuming the seller made the medication.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Ezra failed to respond.